Skip navigationU.S. Food and Drug Administration Center for Drug Evaluation and Research

CDER - Center for Drug Evaluation and Research Logo

Office of Generic Drugs

Reference Listed Drug Labeling and Efficacy Supplements Approved in August 2002
Click on appropriate hyperlink below to view available source document in PDF format
Approval Date

Product Name

Source Documents

Active Ingredient(s)/Dosage Form

Document ID Number
   Aug 1

DARVON

letter        

propoxyphene HCL capsule

10-997 SLR 043

DARVON Cpd

letter        

propoxyphene HCL/aspirin/caffeine capsule

10-996 SLR 061

DARVON-N

letter        

propoxyphene napsylate tablet

16-862 SLR 033
Aug 2

ALTACE

letter        

ramipril capsules

19-901 SLR 034

MALARONE

letter label

atovaquone/proguanil hydrochloride tablets

21-078 SE8 003
Aug 5

ESKALITH CR

letter        

lithium carbonate tablets

18-152 SLR 017

VIDEX EC

letter label

didanosine delayed-release capsules

21-183 SLR 004
Aug 7

DIFLUCAN

letter label

fluconazole tablets

19-949 SLR 033

DIFLUCAN

letter label

fluconazole oral powder

20-090 SLR 015

MONISTAT 3

letter     

miconazole nitrate vaginal

20-827 SLR 006
Aug 8

DDAVP

letter      

desmopressin acetate injection

18-938 SLR 017
Aug 9

ANDRODERM

letter     

testosterone transdermal system

20-489 SLR 010

COMBIVIR

letter       

lamivudine/zidovudine tablets

20-857 SLR 010

NICORETTE

letter     

nicotine polacrilex gum

18-612 SLR 031

NICORETTE

letter      

nicotine polacrilex gum

20-066 SLR 013
Aug 12

BENTYL

letter       

dicyclomine HCl injection

08-370 SLR 030
Aug 13

NICODERM CQ

letter        

nicotine transdermal system

20-165 SLR 020

TRIZIVIR

letter label

abacavir sulfate/lamivudine/zidovudine tablets

21-205 SLR 006
Aug 14

ACTIGALL

letter    

ursodiol capsules

19-594 SLR 021

DIOVAN

letter label

valsarten capsules

21-283 SE1 001

HIVID

letter label

zalcitabine tablets

20-199 SLR 015

ZIAGEN

letter label

abacavir sulfate tablets

20-977 SLR 008

ZIAGEN

letter label

abacavir sulfate oral solution

20-978 SLR 010
Aug 15

NEURONTIN

letter     

gabapentin capsules

20-235 SE8 023

NEURONTIN

letter     

gabapentin tablets

20-882 SE8 009

NEURONTIN

letter     

gabapentin oral solution

21-129 SE8 010
Aug 16

KYTRIL

letter label

granisetron HCl injection

20-239 SE1 008
Aug 20

LEUSTATIN

letter    

cladribine injection

20-229 SLR 007
Aug 21

ADVAIR DISKUS

letter     

fluticasone propionate/salmeterol inh

21-077 SLR 008

MAXIPIME

letter    

cefepime HCl injection

50-679 SLR 009

SPECTRACEF

letter label

cefditoren pivoxil tablets

21-222 SE1 001

STIMATE

letter    

desmopressin acetate nasal spray

20-355 SLR 004
Aug 22

LEUSTATIN

letter    

cladribine injection

20-229 SLR 021
Aug 23

VISINE L.R.

letter       

oxymetazoline HCl ophthalmic solution

19-407 SLR 010
Aug 26

ANTURANE

letter    

sulfinpyrazone

11-556 SLR 053

FIORINAL #3

letter      

butalbital, aspirin, caffeine, and codeine phosphate capsules

19-429 SLR 006

LUMIGAN

letter label

bimatoprost ophthalmic solution

21-275 SLR 006

PROLOPRIM

letter label

trimethoprim tablets

17-943 SLR 016
Aug 27

MEGACE

letter     

megestrol acetate tablets

16-979 SLR 051
Aug 29

COPAXONE

letter      

glatiramer acetate injection,

20-622 SLR 026

LEXAPRO

letter      

escitalopram oxalate tablets

21-323 SE8 001

MONOPRIL

letter     

fosinopril Na tablets

19-915 SLR 032

PERMAX

letter      

pergolide mesylate tablets

19-385 SLR 028

TAXOL

letter       

paclitaxel injection

20-262 SLR 035
Aug 30

NOLVADEX

letter label

tamoxifen tablets

17-970 SLR 050

PREVACID

letter label

lansoprazole

20-406 SLR 052

totop.gif (1525 bytes) Back to Top

Back Labeling Review Branch Page

FDA/Center for Drug Evaluation and Research
Last Updated: January 18, 2006
Originator: OTCOM/DLIS
HTML by JFG